Department of Vascular Surgery - University Hospital, Dijon, France.
Department of Vascular Surgery - University Hospital, Besançon, France.
Ann Vasc Surg. 2023 Jul;93:9-17. doi: 10.1016/j.avsg.2022.06.099. Epub 2022 Jul 22.
Endovascular abdominal aortic aneurysm repair (EVAR) is a safe and minimally invasive alternative to open surgical repair for infra renal aortic aneuvrysm. EVAR requires lifelong post-procedural surveillance. Endoleaks represent the main complication. Type II endoleaks (EL2) are the most frequent and tend to be indolent. Most practitioners do not treat in EL2 as long as they are associated with stable aneurysm diameter. European guidelines recommend treatment in case of aneurysm growth. Several techniques can be offered, such as transarterial embolization and translumbar embolization. This study reports the experience and results of a single center for EL2 endovascular treatment. The aim of this study was to determine more precisely the efficacity of embolization for type 2 endoleaks treatment.
A single center cohort of patients treated for EL2 with endovascular technique between 1998 and 2018 was formed to perform a descriptive analysis. Preoperative sizing, risk factors of endoleaks and intraoperative data were collected. Computed topography (CT) scans were regularly performed after EVAR to detect endoleak recurrence. Clinical recurrence was defined as the persistence of aneurysm sac growth and radiological recurrence was defined as the occurrence of EL2 on a post-embolization CT scan. Data related to reintervention, overall mortality and aneurysm related mortality were also collected. Kaplan-Meier survival analyses were used to determine the rates of reoperation-free survival and recurrence-free survival.
Six hundred seven patients underwent an endovascular treatment for abdominal aorta aneurysm between 1998 and 2018. One hundred forty-five type 2 endoleaks occurred during this period. Nineteen patients (median age 76 years), underwent endovascular treatment for EL2, with immediate success on 15 patients (8 transarterial embolization, 8 direct sac puncture and 3 combined procedures). During follow-up, 5 patients required a new translumbar embolization and 6 required an open surgery for recurrence of the EL2. Six patients died, 2 of them of causes related to the aneurysm. At 59,6 months median follow-up, 53% of the patients presented a radiologic recurrence, with a sac growth of more than 5 mm since last procedure in 4 patients (24%).
Long term clinical recurrence of type 2 endoleaks treated by endovascular procedures appear to be frequent in our experience, leading to several deaths and requiring open surgical treatment.
血管内腹主动脉瘤修复术(EVAR)是治疗肾下主动脉瘤的一种安全且微创的替代开放手术方法。EVAR 需要终身术后监测。内漏是主要并发症。Ⅱ型内漏(EL2)最为常见,且倾向于惰性。大多数医生只要动脉瘤直径稳定,就不会对 EL2 进行治疗。欧洲指南建议在动脉瘤增大时进行治疗。可以提供多种技术,如经动脉栓塞和经皮穿刺栓塞。本研究报告了一家单中心治疗 EL2 的经验和结果。本研究的目的是更精确地确定栓塞治疗 2 型内漏的疗效。
收集了 1998 年至 2018 年间接受血管内技术治疗 EL2 的患者的单中心队列进行描述性分析。收集了术前测量、内漏的危险因素和术中数据。EVAR 后定期进行计算机断层扫描(CT)以检测内漏复发。临床复发定义为动脉瘤囊持续增大,放射学复发定义为栓塞后 CT 扫描出现 EL2。还收集了与再干预、总死亡率和动脉瘤相关死亡率相关的数据。Kaplan-Meier 生存分析用于确定无再手术生存率和无复发生存率。
1998 年至 2018 年间,607 例患者接受了腹主动脉瘤的血管内治疗。在此期间,有 145 例发生 2 型内漏。19 例患者(中位年龄 76 岁)接受了 EL2 的血管内治疗,15 例患者即刻成功(8 例经动脉栓塞、8 例直接囊内穿刺和 3 例联合手术)。在随访期间,5 例患者需要再次经皮穿刺栓塞,6 例患者因 EL2 复发需要开放手术。6 例患者死亡,其中 2 例与动脉瘤有关。在中位随访 59.6 个月时,53%的患者出现放射学复发,4 例患者(24%)最后一次手术后囊径增长超过 5mm。
在我们的经验中,经血管内治疗的 2 型内漏的长期临床复发似乎很常见,导致数例死亡,并需要开放手术治疗。